Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Mar 01, 2009 (Vol. 29, No. 5)

In the Pipeline

  • Great writing, perspectives
  • None
In the Pipeline is a blog from Derek Lowe, described as a Ph.D. organic chemist who is an Arkansonian by birth. I’m not sure how that all fits together, though. At his site, visitors get Derek’s views of the world of medicinal/organic chemistry, and these are quite fun reading. You don’t have to be a chemistry nerd to appreciate what Derek has to say, though it certainly doesn’t hurt. I found his writing to be both insightful and informative. Whether he is talking about the nastiness of cyanogen or the news of the latest Pfizer layoffs, Derek has a voice worth listening to. You can give him feedback at the site and if you tire of his opinions, the site’s links to related blogs will surely yield something of interest. His own site has archives going back to (gulp) 2002. An excellent site that shows what just one guy can do. In the Pipeline is a must-see.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »